AU2413992A - Method of treating premenstrual syndrome by administration of an angiotensin converting enzyme inhibitor - Google Patents

Method of treating premenstrual syndrome by administration of an angiotensin converting enzyme inhibitor

Info

Publication number
AU2413992A
AU2413992A AU24139/92A AU2413992A AU2413992A AU 2413992 A AU2413992 A AU 2413992A AU 24139/92 A AU24139/92 A AU 24139/92A AU 2413992 A AU2413992 A AU 2413992A AU 2413992 A AU2413992 A AU 2413992A
Authority
AU
Australia
Prior art keywords
administration
converting enzyme
enzyme inhibitor
angiotensin converting
premenstrual syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24139/92A
Inventor
Anthony Salvator Depadova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2413992A publication Critical patent/AU2413992A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU24139/92A 1991-08-05 1992-08-03 Method of treating premenstrual syndrome by administration of an angiotensin converting enzyme inhibitor Abandoned AU2413992A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US740557 1985-06-03
US74055791A 1991-08-05 1991-08-05

Publications (1)

Publication Number Publication Date
AU2413992A true AU2413992A (en) 1993-03-02

Family

ID=24977040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24139/92A Abandoned AU2413992A (en) 1991-08-05 1992-08-03 Method of treating premenstrual syndrome by administration of an angiotensin converting enzyme inhibitor

Country Status (4)

Country Link
AU (1) AU2413992A (en)
MX (1) MX9204528A (en)
PT (1) PT100759A (en)
WO (1) WO1993002679A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
MXPA02010452A (en) 2000-05-11 2003-06-06 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues.
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7899527B2 (en) * 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase

Also Published As

Publication number Publication date
WO1993002679A1 (en) 1993-02-18
PT100759A (en) 1993-09-30
MX9204528A (en) 1993-02-01

Similar Documents

Publication Publication Date Title
AU7714594A (en) Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
AU5533094A (en) Enzyme inhibitors
AU5621594A (en) 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
AU7168696A (en) Inhibitors of regulatory pathways
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU1123595A (en) Method for the oxidation of carbohydrates
AU2103295A (en) Methods for the treatment of thrombosis
AUPN271295A0 (en) Method of treatment
AU3479593A (en) Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
AU1417092A (en) 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
AU6018894A (en) Method of inhibiting viral reproduction
AU2561092A (en) Method of producing an improved one-piece band clamp
AU2719392A (en) Method for treating etchant
AU2251892A (en) Inhibitors of picornavirus proteases
AU4868493A (en) Method of combining polymers
AU7421894A (en) Half nut capable of engaging resiliently another half nut
AU8155294A (en) Methods of inhibiting sexual precocity
AU4479096A (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
AU2277597A (en) New inhibitors of sh2-mediated processes
ZA9610798B (en) Inhibitors of interleuken-1beta converting enzyme
AU2413992A (en) Method of treating premenstrual syndrome by administration of an angiotensin converting enzyme inhibitor
AU4118193A (en) Tetronic, thiotetronic and tetramic acid derivatives as phospholipase A2 inhibitors
AU7596994A (en) Methods and compositions for retarding the aging process
AU2882592A (en) Methods for treatment of hyperlipidemia using azaspiranes
AU1779192A (en) Method of treatment using steroid mouthwash